Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $PLSE
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/10/2022 | $43.00 → $20.00 | Buy | HC Wainwright & Co. |
11/16/2021 | $46.00 → $43.00 | Buy | HC Wainwright & Co. |
7/27/2021 | $28.00 | Overweight | Stephens & Co. |
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P
HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously
HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target
HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously
Stephens & Co. initiated coverage on Pulse Biosciences with a new price target
Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00
Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Director Zanganeh Mahkam exercised 60,242 in-the-money shares at a strike of $11.00, increasing direct ownership by 9% to 725,395 units (SEC Form 4)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
SEC Form 4 filed by Chief Executive Officer Laviolette Paul A
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Former President and CEO Barrett Burke Thomas sold $871,000 worth of shares (50,000 units at $17.42), decreasing direct ownership by 44% to 63,172 units (SEC Form 4)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
SEC Form S-8 filed by Pulse Biosciences Inc
S-8 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
SEC Form S-8 filed by Pulse Biosciences Inc
S-8 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in
Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc
SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)